Clinical trial
Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage…
NCT00268489 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00268489 |
|---|---|
| Title | Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer |
| Official title | A Phase II Study of Pemetrexed Disodium (ALIMTA®) Plus Bevacizumab in Patients With Stage IIIB Pleural Effusion or Stage IV Non-Small Cell Lung Cancer (Second-Line Treatment) |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, pemetrexed disodium |
| Enrollment | 48 |
| Start date | May 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | Apr 1, 2010 |
| First posted | Dec 22, 2005 |
| Last update posted | Jul 6, 2016 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: